JPRN-UMIN000045097
Completed
未知
Prospective study on evaluation of immunological response after SARS-CoV-2 vaccination - Prospective study on evaluation of immunological response after SARS-CoV-2 vaccination
Shionogi & Co., Ltd.0 sites205 target enrollmentAugust 9, 2021
ConditionsCOVID-19
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Shionogi & Co., Ltd.
- Enrollment
- 205
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. For male, those who more than 200 mL of their whole blood or blood component has been lost within 12 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition. For female, those who more than 200 mL of their whole blood or blood component has been lost within 16 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition. 2\. Those who participated in other clinical studies within 30 days before consent acquisition, or are participating in other clinical studies except for "Observational study on the evaluation of COVID\-19 prevention and subjects' health status after SARS\-CoV\-2 vaccination" conducted by Shionogi \& Co., Ltd.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
Active, not recruiting
Phase 1
A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK) - P13UKPrevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia and pneumonia.EUCTR2010-023865-22-GBHealth Protection Agency
Completed
Phase 4
Responses to booster vaccinations in UK toddlersISRCTN84763401Health Protection Agency (UK)200
Completed
Phase 4
Influenza Specific Immunity After Vaccination in Recipients of Haematopoietic Stem Cell Transplantation Compared to Healthy ControlsHaematopoietic Stem Cell Transplant patientscancerhaematological malignancyAutologous or allogeneicInfluenzaCancer - Any cancerInfection - Other infectious diseasesInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12614000240640Princess Margaret Hospital for children150
Active, not recruiting
Phase 1
Effect of rituximab in secondary progressive multiple sclerosisEUCTR2012-004436-36-DKOdense University Hospital15